| CAS NO: | 76824-35-6 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| Molecular Weight (MW) | 337.45 |
|---|---|
| Formula | C8H15N7O2S3 |
| CAS No. | 76824-35-6 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 67 mg/mL (198.5 mM) |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| Other info | Chemical Name: (Z)-3-(((2-((diaminomethylene)amino)thiazol-4-yl)methyl)thio)-N'-sulfamoylpropanimidamide InChi Key: XUFQPHANEAPEMJ-UHFFFAOYSA-N InChi Code: InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14) SMILES Code: N/C(N)=N\C1=NC(CSCC/C(N)=N/S(=O)(N)=O)=CS1 |
| Synonyms | MK-208; MK 208, Pepcid, YM-11170, MK208; MK-208, YM11170, YM 11170 |
| In Vitro | In vitro activity: Famotidine (also known as MK208) is a histamine H2–receptor antagonist with IC50 of 0.6 mM, it inhibits stomach acid production and therefore is commonly used to treat heartburn, GERD, ulcers, and other digestive conditions. Unlike cimetidine, the first H2 antagonist, famotidine has no effect on the cytochrome P450 enzyme system, and does not appear to interact with other drugs. |
|---|---|
| In Vivo | Famotidine (MK-208) is a histamine H2-receptor antagonist that inhibits stomach acid production, and it is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). Famotidine (MK-208) Group(2 mg/kg/day) were significantly lower than the equivalent parameters for the Control Group on both the third and seventh days post-surgery. Famotidine (MK-208) exerts detrimental effects on the anastomotic bursting pressure and hydroxyproline content of perianastomotic tissues in the colon of rats. Famotidine (MK-208) increased the transgastric potential difference (PD) and promoted the recovery of decreased transgastric PD induced by acidified ethanol in rats. The preventive effect of famotidine on gastric lesions is attributable not only to suppression of acid secretion but to activation of the gastric mucosal defensive mechanisms. |
| Animal model | Rats |
| Formulation & Dosage | 2 mg/kg |
| References | Clinics (Sao Paulo), 2009. 64(6): p. 567-70.; Jpn J Pharmacol, 1991. 55(2): p. 211-22. |
m.cnreagent.com